- Home
- RNXT vs PMN Comparison
RNXT vs PMN Comparison
Compare RNXT & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RNXT | PMN |
|---|---|---|
| Founded | 2012 | 2004 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Pharmaceuticals and Biotechnology |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.4M | 23.5M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | RNXT | PMN |
|---|---|---|
| Price | $1.04 | $7.69 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $7.75 | ★ $72.67 |
| AVG Volume (30 Days) | ★ 202.4K | 24.4K |
| Earning Date | 11-13-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $928,000.00 | N/A |
| Revenue This Year | $2,795.35 | N/A |
| Revenue Next Year | $272.69 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.70 | $6.27 |
| 52 Week High | $1.69 | $39.75 |
Technical Indicators
Market Signals| Indicator | RNXT | PMN |
|---|---|---|
| Relative Strength Index (RSI) | 61.75 | 61.62 |
| Support Level | $0.84 | $6.62 |
| Resistance Level | $0.92 | $8.73 |
| Average True Range (ATR) | 0.08 | 0.55 |
| MACD | 0.01 | -0.38 |
| Stochastic Oscillator | 96.30 | 42.32 |
Price Performance
Historical ComparisonAbout RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
About PMN ProMIS Neurosciences Inc. (ON)
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.